Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients
Open Access
- 1 November 1991
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 64 (5) , 887-894
- https://doi.org/10.1038/bjc.1991.420
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancerCancer Chemotherapy and Pharmacology, 1991
- POTENCY AND SELECTIVITY OF THE NON-STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTSClinical Endocrinology, 1990
- Metabolic Clearance Rate (MCR) of Dehydroepiandrosterone Sulfate (DS), Its Metabolism to Dehydroepiandrosterone, Androstenedione, Testosterone, and Dihydrotestosterone, and the Effect of Increased Plasma DS Concentration on DS MCR in Normal Women *Journal of Clinical Endocrinology & Metabolism, 1989
- ENDOCRINE EFFECTS OF LOW DOSE AMINOGLUTETHIMIDE AS AN AROMATASE INHIBITOR IN THE TREATMENT OF BREAST CANCERClinical Endocrinology, 1985
- Analogs of aminoglutethimide: selective inhibition of aromataseJournal of Medicinal Chemistry, 1985
- Single-Dose and Steady-State Pharmacokinetics of AminoglutethimideClinical Pharmacokinetics, 1985
- 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCERThe Lancet, 1984
- Endocrine Changes Associated with Relapse in Advanced Breast Cancer Patients on Aminoglutethimide TherapyJournal of Clinical Endocrinology & Metabolism, 1984
- Aminoglutethimide dose and hormone suppression in advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1983
- Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast CancerJournal of Clinical Endocrinology & Metabolism, 1982